PL361103A1 - Trójcykliczne związki przeciwrakowe będące inhibitorami transferazy farnezyloproteinowej - Google Patents

Trójcykliczne związki przeciwrakowe będące inhibitorami transferazy farnezyloproteinowej

Info

Publication number: PL361103A1
Authority: PL; Poland
Prior art keywords: protein transferase; transferase inhibitors; farnesyl protein; antitumor compounds; tricyclic
Prior art date: 2000-08-30

Application number

PL01361103A

Other languages

English (en)

Inventor

F.George Njoroge

Bancha Vibulbhan

Alan B. Cooper

Timothy Guzi

Dinanath F. Rane

Keith P. Minor

Ronald J. Doll

Viyyoor Moopil Girijavallabhan

Bama Santhanam

Patrick A. Pinto

Hugh Y. Zhu

Kartik M. Keertikar

Carmen S. Alvarez

John J. Baldwin

Ge Li

Chia-Yu Huang

Ray A. James

Robert W. Bishop

James Wang

Jagdish A. Desai

Original Assignee

Schering Corporation

Pharmacopeia, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-30

Filing date

2001-08-28

Publication date

2004-09-20

2001-08-28 Application filed by Schering Corporation, Pharmacopeia, Inc. filed Critical Schering Corporation

2004-09-20 Publication of PL361103A1 publication Critical patent/PL361103A1/pl

Links

230000000259 anti-tumor effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL01361103A 2000-08-30 2001-08-28 Trójcykliczne związki przeciwrakowe będące inhibitorami transferazy farnezyloproteinowej PL361103A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22918300P	2000-08-30	2000-08-30
PCT/US2001/026792 WO2002018368A1 (en)	2000-08-30	2001-08-28	Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Publications (1)

Publication Number	Publication Date
PL361103A1 true PL361103A1 (pl)	2004-09-20

Family

ID=22860141

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01361103A PL361103A1 (pl)	2000-08-30	2001-08-28	Trójcykliczne związki przeciwrakowe będące inhibitorami transferazy farnezyloproteinowej

Country Status (27)

Country	Link
US (1)	US20020198216A1 (pl)
EP (1)	EP1313725B1 (pl)
JP (1)	JP2004513885A (pl)
KR (1)	KR20030034161A (pl)
CN (1)	CN100384837C (pl)
AR (1)	AR033680A1 (pl)
AT (1)	ATE359281T1 (pl)
AU (2)	AU2001288451C1 (pl)
BR (1)	BR0113675A (pl)
CA (1)	CA2420673A1 (pl)
CO (1)	CO5640109A2 (pl)
DE (1)	DE60127846T2 (pl)
EC (1)	ECSP034494A (pl)
ES (1)	ES2284686T3 (pl)
HK (1)	HK1054548B (pl)
HU (1)	HUP0302942A3 (pl)
IL (1)	IL154528A0 (pl)
MX (1)	MXPA03001849A (pl)
NO (1)	NO20030918L (pl)
NZ (1)	NZ524246A (pl)
PE (1)	PE20020486A1 (pl)
PL (1)	PL361103A1 (pl)
RU (1)	RU2293734C9 (pl)
SK (1)	SK2292003A3 (pl)
TW (1)	TWI268280B (pl)
WO (1)	WO2002018368A1 (pl)
ZA (1)	ZA200301545B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7342016B2 (en)	2000-08-30	2008-03-11	Schering Corporation	Farnesyl protein transferase inhibitors as antitumor agents
ATE554756T1 (de)	2001-03-14	2012-05-15	Bristol Myers Squibb Co	Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
JP2005531488A (ja) *	2001-10-09	2005-10-20	ザ・ユニバーシティ・オブ・シンシナティ	甲状腺癌を処置するためのｅｇｆ受容体阻害剤
WO2003047697A2 (en) *	2001-11-30	2003-06-12	Schering Corporation	Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
EP1453513A1 (en) *	2001-12-03	2004-09-08	Schering Corporation	Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20030195192A1 (en) *	2002-04-05	2003-10-16	Fortuna Haviv	Nicotinamides having antiangiogenic activity
US20040014744A1 (en) *	2002-04-05	2004-01-22	Fortuna Haviv	Substituted pyridines having antiangiogenic activity
WO2004094409A1 (en)	2003-03-27	2004-11-04	Lankenau Institute For Medical Research	Novel ido inhibitors and methods of use
EP1628631A2 (en) *	2003-06-05	2006-03-01	Achkar, Charles C.	Methods of treating hyperproliferative cell disorders
US20070036795A1 (en) *	2003-06-09	2007-02-15	Samuel Waksal	Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
ES2235611B2 (es) *	2003-07-25	2006-07-16	Universidade De Santiago De Compostela	Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas.
RU2006106768A (ru) *	2003-08-07	2007-09-20	Шеринг Корпорейшн (US)	Новые ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты
US7592466B2 (en)	2003-10-09	2009-09-22	Abbott Laboratories	Ureas having antiangiogenic activity
WO2006069208A2 (en) *	2004-12-21	2006-06-29	Schering Corporation	Novel farnesyl protein transferase inhibitors as antitumor agents
RU2361587C1 (ru) *	2008-02-14	2009-07-20	Михаил Владимирович Кутушов	Лекарственное средство для лечения онкологических заболеваний
EP2313091A4 (en) *	2008-07-14	2012-04-04	Univ Kingston	PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
EP3989956A1 (en) *	2019-06-28	2022-05-04	Anhui Ronghang Biotech Development Co., Ltd.	Compositions and methods for treatment of hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5089496A (en) *	1986-10-31	1992-02-18	Schering Corporation	Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
NZ238629A (en) *	1990-06-22	1993-09-27	Schering Corp	Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
US5719148A (en) *	1993-10-15	1998-02-17	Schering Corporation	Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) *	1996-07-31	1998-12-31	Schering Corp	N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) *	1996-09-13	2000-06-06	Schering Corporation	Tricyclic compounds useful as FPT inhibitors
US5925648A (en) *	1997-07-29	1999-07-20	Schering Corporation	Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
SK7582001A3 (en) *	1998-12-18	2002-03-05	Schering Corp	Compound, method of therapy and pharmaceutical composition comprising the same, and its use for farnesyl protein transferase inhibition

2001
- 2001-08-27 AR ARP010104082A patent/AR033680A1/es unknown
- 2001-08-28 SK SK229-2003A patent/SK2292003A3/sk not_active Application Discontinuation
- 2001-08-28 AU AU2001288451A patent/AU2001288451C1/en not_active Ceased
- 2001-08-28 MX MXPA03001849A patent/MXPA03001849A/es active IP Right Grant
- 2001-08-28 KR KR10-2003-7003012A patent/KR20030034161A/ko not_active Ceased
- 2001-08-28 JP JP2002523486A patent/JP2004513885A/ja active Pending
- 2001-08-28 NZ NZ524246A patent/NZ524246A/en unknown
- 2001-08-28 DE DE60127846T patent/DE60127846T2/de not_active Expired - Fee Related
- 2001-08-28 US US09/940,811 patent/US20020198216A1/en not_active Abandoned
- 2001-08-28 HU HU0302942A patent/HUP0302942A3/hu unknown
- 2001-08-28 EP EP01968188A patent/EP1313725B1/en not_active Expired - Lifetime
- 2001-08-28 PE PE2001000865A patent/PE20020486A1/es not_active Application Discontinuation
- 2001-08-28 AU AU8845101A patent/AU8845101A/xx active Pending
- 2001-08-28 TW TW090121201A patent/TWI268280B/zh active
- 2001-08-28 WO PCT/US2001/026792 patent/WO2002018368A1/en not_active Ceased
- 2001-08-28 HK HK03105016.6A patent/HK1054548B/en not_active IP Right Cessation
- 2001-08-28 AT AT01968188T patent/ATE359281T1/de not_active IP Right Cessation
- 2001-08-28 PL PL01361103A patent/PL361103A1/pl unknown
- 2001-08-28 RU RU2003108865/04A patent/RU2293734C9/ru not_active IP Right Cessation
- 2001-08-28 CN CNB01818121XA patent/CN100384837C/zh not_active Expired - Fee Related
- 2001-08-28 BR BR0113675-5A patent/BR0113675A/pt not_active IP Right Cessation
- 2001-08-28 ES ES01968188T patent/ES2284686T3/es not_active Expired - Lifetime
- 2001-08-28 IL IL15452801A patent/IL154528A0/xx unknown
- 2001-08-28 CA CA002420673A patent/CA2420673A1/en not_active Abandoned
2003
- 2003-02-25 ZA ZA200301549A patent/ZA200301545B/xx unknown
- 2003-02-26 EC EC2003004494A patent/ECSP034494A/es unknown
- 2003-02-27 NO NO20030918A patent/NO20030918L/no not_active Application Discontinuation
- 2003-02-27 CO CO03017118A patent/CO5640109A2/es active IP Right Grant

Also Published As

Publication number	Publication date
WO2002018368A1 (en)	2002-03-07
HUP0302942A2 (hu)	2003-12-29
NO20030918D0 (no)	2003-02-27
ES2284686T3 (es)	2007-11-16
NZ524246A (en)	2004-11-26
AR033680A1 (es)	2004-01-07
MXPA03001849A (es)	2003-06-04
PE20020486A1 (es)	2002-06-14
US20020198216A1 (en)	2002-12-26
ATE359281T1 (de)	2007-05-15
IL154528A0 (en)	2003-09-17
TWI268280B (en)	2006-12-11
DE60127846D1 (en)	2007-05-24
NO20030918L (no)	2003-04-29
EP1313725B1 (en)	2007-04-11
KR20030034161A (ko)	2003-05-01
EP1313725A1 (en)	2003-05-28
CA2420673A1 (en)	2002-03-07
AU2001288451C1 (en)	2008-03-06
AU2001288451B2 (en)	2007-05-24
CN1471524A (zh)	2004-01-28
CN100384837C (zh)	2008-04-30
BR0113675A (pt)	2003-06-24
SK2292003A3 (en)	2003-08-05
ZA200301545B (en)	2004-06-22
AU8845101A (en)	2002-03-13
JP2004513885A (ja)	2004-05-13
CO5640109A2 (es)	2006-05-31
HK1054548B (en)	2007-10-18
RU2293734C9 (ru)	2007-10-10
HK1054548A1 (en)	2003-12-05
DE60127846T2 (de)	2008-03-06
ECSP034494A (es)	2003-04-25
HUP0302942A3 (en)	2007-02-28
RU2293734C2 (ru)	2007-02-20

Publication	Publication Date	Title
AU2001240658A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations with camptothecin compounds
AU8845101A (en)	2002-03-13	Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
AU2001246477A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations with platinum compounds
IL143409A0 (en)	2002-04-21	Farnesyl protein transferase inhibitors
AU2001235496A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
AU2001234484A1 (en)	2001-07-31	Amide compounds for inhibiting protein kinases
AU2001239275A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001293835A1 (en)	2002-04-02	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
NO996571D0 (no)	1999-12-30	Inhibitorer for farnesyl-protein-transferase
AU2001247882A1 (en)	2001-10-08	Tricyclic protein kinase inhibitors
AU2001244166A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AU2001252147A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations
AU2001246478A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001253197A1 (en)	2001-11-07	Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
AU2001256166A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
IL163673A0 (en)	2005-12-18	Farnesyl protein transferase inhibitors as antitumor agents
IL173514A0 (en)	2006-07-05	Novel farnesyl protein transferase inhibitors as antitumor agents
AU2001244167A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
IL143408A0 (en)	2002-04-21	Tricyclic farnesyl protein transferase inhibitors
DK1339695T3 (da)	2006-07-31	Farnesyltransferase-inhibitorer
AU2001242434A1 (en)	2001-09-12	Farnesyl protein transferase inhibitor combinations with vinca alkaloids
PL355887A1 (pl)	2004-05-31	Inhibitory transferazy farnezylowej
AU2435199A (en)	1999-08-30	Farnesyl transferase inhibitors
AU3514302A (en)	2002-06-11	0ovel farnesyl protein transferase inhibitors
HK1036975A (en)	2002-01-25	Tricyclic farnesyl protein transferase inhibitors